Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients

G. M. van Dam; M. Koller; S. Q. Qiu; M. D. Linssen; J. de Vries; L. Jansen; W. Kelder; J. S. de Jong; A. Jorritsma-Smit; B. van der Vegt; D. J. Robinson; W. B. Nagengast

doi:10.1158/1538-7445.SABCS16-P4-01-01

Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients

G. M. van Dam, M. Koller, S. Q. Qiu, M. D. Linssen, J. de Vries, L. Jansen, W. Kelder, J. S. de Jong, A. Jorritsma-Smit, B. van der Vegt, D. J. Robinson, W. B. Nagengast

Onderzoeksoutput › Academic

Originele taal-2	English
Pagina's (van-tot)	P4-01-01
Aantal pagina's	3
Tijdschrift	Cancer Research
Volume	77
Nummer van het tijdschrift	4 supp
DOI's	https://doi.org/10.1158/1538-7445.SABCS16-P4-01-01
Status	Published - feb.-2017
Evenement	San Antonio Breast Cancer Symposium - San Antonio Duur: 6-dec.-2016 → 10-dec.-2016

Toegang tot document

10.1158/1538-7445.SABCS16-P4-01-01

Handle.net

Permanente koppeling

Citeer dit

van Dam, G. M., Koller, M., Qiu, S. Q., Linssen, M. D., de Vries, J., Jansen, L., Kelder, W., de Jong, J. S., Jorritsma-Smit, A., van der Vegt, B., Robinson, D. J., & Nagengast, W. B. (2017). Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients. Cancer Research, 77(4 supp), P4-01-01. https://doi.org/10.1158/1538-7445.SABCS16-P4-01-01

@article{edc4aa2a5bf54f67b09c24c32b9f79bf,

title = "Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients",

author = "{van Dam}, {G. M.} and M. Koller and Qiu, {S. Q.} and Linssen, {M. D.} and {de Vries}, J. and L. Jansen and W. Kelder and {de Jong}, {J. S.} and A. Jorritsma-Smit and {van der Vegt}, B. and Robinson, {D. J.} and Nagengast, {W. B.}",

year = "2017",

month = feb,

doi = "10.1158/1538-7445.SABCS16-P4-01-01",

language = "English",

volume = "77",

pages = "P4--01--01",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "AMER ASSOC CANCER RESEARCH",

number = "4 supp",

note = "San Antonio Breast Cancer Symposium ; Conference date: 06-12-2016 Through 10-12-2016",

}

van Dam, GM, Koller, M, Qiu, SQ, Linssen, MD, de Vries, J, Jansen, L, Kelder, W, de Jong, JS, Jorritsma-Smit, A, van der Vegt, B, Robinson, DJ & Nagengast, WB 2017, 'Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients', Cancer Research, vol. 77, nr. 4 supp, blz. P4-01-01. https://doi.org/10.1158/1538-7445.SABCS16-P4-01-01

TY - JOUR

T1 - Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients

AU - van Dam, G. M.

AU - Koller, M.

AU - Qiu, S. Q.

AU - Linssen, M. D.

AU - de Vries, J.

AU - Jansen, L.

AU - Kelder, W.

AU - de Jong, J. S.

AU - Jorritsma-Smit, A.

AU - van der Vegt, B.

AU - Robinson, D. J.

AU - Nagengast, W. B.

PY - 2017/2

Y1 - 2017/2

U2 - 10.1158/1538-7445.SABCS16-P4-01-01

DO - 10.1158/1538-7445.SABCS16-P4-01-01

M3 - Meeting Abstract

SN - 0008-5472

VL - 77

SP - P4-01-01

JO - Cancer Research

JF - Cancer Research

IS - 4 supp

T2 - San Antonio Breast Cancer Symposium

Y2 - 6 December 2016 through 10 December 2016

ER -